Abstract
Complications involved with the progression of atherosclerosis in the coronary arteries are responsible for the majority of deaths related to cardiovascular disease. Clinically, X-ray computed tomography (CT) plays a key role in the assessment of atherosclerosis but current iodinated contrast agents relied upon for CT applications suffer from fast clearance, biocompatibility issues, and nonspecific uptake. Nanotechnologies have presented solutions to these problems by offering precise control over the properties of novel contrast agents. In this chapter, we discuss nanoparticle CT contrast agents that have been used for cardiovascular imaging. We cover iodinated and inorganic nanoparticle structures including nano-emulsions, liposomes, micelles, dendrimers, solid metal core nanoparticles, and others and discuss their applications for vascular and target specific imaging. Tremendous progress has been made in the field over the past decade and we expect that the next decade will see the clinical translation of nanoparticle formulations among many additional technological advances.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics- 2015 update: a report from the American heart association. Circulation. 2015;131(4):e29–322.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American heart association. Circulation. 2014;129(3):e28–292.
Lumbroso P, Dick CE. X-ray attenuation properties of radiographic contrast media. Med Phys. 1987;14(5):752–8.
Lee N, Choi SH, Hyeon T. Nano-sized CT contrast agents. Adv Mater. 2013;25(19):2641–60.
Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379–93.
Stone PH, Coskun AU, Yeghiazarians Y, Kinlay S, Popma JJ, Kuntz RE, et al. Prediction of sites of coronary atherosclerosis progression: in vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol. 2003;18(6):458–70.
Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417(6890):750–4.
Srinivasan SR, Vijayagopal P, Dalferes Jr ER, Abbate B, Radhakrishnamurthy B, Berenson GS. Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. Atherosclerosis. 1986;62(3):201–8.
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for vcam-1, but not icam-1, in early atherosclerosis. J Clin Invest. 2001;107(10):1255–62.
Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000;87(2):153–9.
Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ, et al. Direct demonstration of p-selectin- and vcam-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein e-deficient mice. Circ Res. 1999;84(11):1237–44.
Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, et al. Up-regulated expression of the cxcr2 ligand kc/gro-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol. 2006;168(4):1385–95.
Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in ccr2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394(6696):894–7.
Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of ccl2, cx3cr1, and ccr5 abrogates ly6c(hi) and ly6c(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117(13):1649–57.
Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005;11(23):3061–72.
Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.
Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994;90(2):775–8.
Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008;117(25):3206–15.
Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114(14):1504–11.
Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117(3):379–87.
Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol. 2009;29(10):1444–51.
Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(9):2103–9.
Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fujii DK. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001;13(4):615–8.
Tota-Maharaj R, Al-Mallah MH, Nasir K, Qureshi WT, Blumenthal RS, Blaha MJ. Improving the relationship between coronary artery calcium score and coronary plaque burden: addition of regional measures of coronary artery calcium distribution. Atherosclerosis. 2015;238(1):126–31.
Hou ZH, Lu B, Gao Y, Jiang SL, Wang Y, Li W, et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging. 2012;5(10):990–9.
Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493–503.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–72.
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981–8.
Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, et al. Molecular mri detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging. 2009;2(6):468–75.
Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356(9225):209–12.
Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437–45.
Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118(2):140–8.
Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol. 2009;54(2):130–8.
Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik DE, Aikawa E, et al. Impaired infarct healing in atherosclerotic mice with ly-6c(hi) monocytosis. J Am Coll Cardiol. 2010;55(15):1629–38.
Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology. 2008;247(3):788–96.
van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008;52(24):2017–28.
Yonezawa M, Nagata M, Kitagawa K, Kato S, Yoon Y, Nakajima H, et al. Quantitative analysis of 1.5-t whole-heart coronary MR angiograms obtained with 32-channel cardiac coils: a comparison with conventional quantitative coronary angiography. Radiology. 2014;271(2):356–64.
Health QO. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(16):1–80.
Sarikaya I. Cardiac applications of PET. Nucl Med Commun. 2015;36(10):971–85.
Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-f] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777.
Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med. 2015;56(4):552–9.
Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51(6):862–5.
Bardo DM, Brown P. Cardiac multidetector computed tomography: basic physics of image acquisition and clinical applications. Curr Cardiol Rev. 2008;4(3):231–43.
Otero HJ, Steigner ML, Rybicki FJ. The “post-64” era of coronary CT angiography: understanding new technology from physical principles. Radiol Clin North Am. 2009;47(1):79–90.
Flohr TG, McCollough CH, Bruder H, Petersilka M, Gruber K, Suss C, et al. First performance evaluation of a dual-source CT (DSCT) system. Eur Radiol. 2006;16(2):256–68.
Dewey M, Teige F, Laule M, Hamm B. Influence of heart rate on diagnostic accuracy and image quality of 16-slice CT coronary angiography: comparison of multisegment and halfscan reconstruction approaches. Eur Radiol. 2007;17(11):2829–37.
Hoffmann U, Pena AJ, Cury RC, Abbara S, Ferencik M, Moselewski F, et al. Cardiac CT in emergency department patients with acute chest pain. Radiographics. 2006;26(4):963–78. discussion 79-80.
Lee NJ, Litt H. Cardiac CT angiography for evaluation of acute chest pain. Int J Cardiovasc Imaging. 2015.
Goldberg A, Litt HI. Evaluation of the patient with acute chest pain. Radiol Clin North Am. 2010;48(4):745–55.
Achenbach S, Daniel WG. Cardiac imaging in the patient with chest pain: coronary CT angiography. Heart. 2010;96(15):1241–6.
Nasis A, Mottram PM, Cameron JD, Seneviratne SK. Current and evolving clinical applications of multidetector cardiac CT in assessment of structural heart disease. Radiology. 2013;267(1):11–25.
Puchner SB, Liu T, Mayrhofer T, Truong QA, Lee H, Fleg JL, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the Romicat-II trial. J Am Coll Cardiol. 2014;64(7):684–92.
Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334(26):1703–8.
Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve scientific basis. J Am Coll Cardiol. 2013;61(22):2233–41.
Bittencourt MS, Achenbach S, Marwan M, Seltmann M, Muschiol G, Ropers D, et al. Left ventricular thrombus attenuation characterization in cardiac computed tomography angiography. J Cardiovasc Comput Tomogr. 2012;6(2):121–6.
Grude M, Juergens KU, Wichter T, Paul M, Fallenberg EM, Muller JG, et al. Evaluation of global left ventricular myocardial function with electrocardiogram-gated multidetector computed tomography: comparison with magnetic resonance imaging. Invest Radiol. 2003;38(10):653–61.
Galper MW, Saung MT, Fuster V, Roessl E, Thran A, Proksa R, et al. Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast. Invest Radiol. 2012;47(8):475–81.
Oliva MR, Erturk SM, Ichikawa T, Rocha T, Ros PR, Silverman SG, et al. Gastrointestinal tract wall visualization and distention during abdominal and pelvic multidetector CT with a neutral barium sulphate suspension: comparison with positive barium sulphate suspension and with water. JBR-BTR. 2012;95(4):237–42.
Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010;256(1):32–61.
Weininger M, Barraza JM, Kemper CA, Kalafut JF, Costello P, Schoepf UJ. Cardiothoracic CT angiography: current contrast medium delivery strategies. Am J Roentgenol. 2011;196(3):W260–72.
Fleischmann D, Kamaya A. Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am. 2009;47(1):13–26.
Bourin M, Jolliet P, Ballereau F. An overview of the clinical pharmacokinetics of X-ray contrast media. Clin Pharmacokinet. 1997;32(3):180–93.
Watchorn J, Miles R, Moore N. The role of CT angiography in military trauma. Clin Radiol. 2013;68(1):39–46.
Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–71.
Thomsen HS, Morcos SK. Contrast media and the kidney: European society of urogenital radiology (ESUR) guidelines. Br J Radiol. 2003;76(908):513–8.
Jun YW, Choi JS, Cheon J. Shape control of semiconductor and metal oxide nanocrystals through nonhydrolytic colloidal routes. Angew Chem Int Ed Engl. 2006;45(21):3414–39.
Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the us adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127–33.
Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist. Mayo Clin Proc. 2012;87(4):390–402.
Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging. 2014;9(1):37–52.
Chhour P, Gallo N, Cheheltani R, Williams D, Al-Zaki A, Paik T, et al. Nanodisco balls: control over surface versus core loading of diagnostically active nanocrystals into polymer nanoparticles. ACS Nano. 2014;8(9):9143–53.
Jarzyna PA, Gianella A, Skajaa T, Knudsen G, Deddens LH, Cormode DP, et al. Multifunctional imaging nanoprobes. Wires Nanomed Nanobi. 2010;2(2):138–50.
van Schooneveld MM, Cormode DP, Koole R, van Wijngaarden JT, Calcagno C, Skajaa T, et al. A fluorescent, paramagnetic and pegylated gold/silica nanoparticle for MRI, CT and fluorescence imaging. Contrast Media Mol Imaging. 2010;5(4):231–6.
Mieszawska AJ, Kim Y, Gianella A, van Rooy I, Priem B, Labarre MP, et al. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy. Bioconjug Chem. 2013;24(9):1429–34.
Satomi T, Nagasaki Y, Kobayashi H, Tateishi T, Kataoka K, Otsuka H. Physicochemical characterization of densely packed poly(ethylene glycol) layer for minimizing nonspecific protein adsorption. J Nanosci Nanotechnol. 2007;7(7):2394–9.
Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481–503.
Almeida JP, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond). 2011;6(5):815–35.
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–15.
Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8(7):751–5.
Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, et al. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2008;8(12):4593–6.
Liu J, Wong HL, Moselhy J, Bowen B, Wu XY, Johnston MR. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer. 2006;51(3):377–86.
Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006;19(1):142–64.
Bhattacharya S, Novell JR, Winslet MC, Hobbs KE. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg. 1994;81(11):1563–71.
Lim JS, Choi J, Song J, Chung YE, Lim SJ, Lee SK, et al. Nanoscale iodized oil emulsion: a useful tracer for pretreatment sentinel node detection using CT lymphography in a normal canine gastric model. Surg Endosc. 2012;26(8):2267–74.
Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am. 2003;12(1):105–26.
Kong WH, Lee WJ, Cui ZY, Bae KH, Park TG, Kim JH, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials. 2007;28(36):5555–61.
Weichert JP, Longino MA, Bakan DA, Spigarelli MG, Chou TS, Schwendner SW, et al. Polyiodinated triglyceride analogs as potential computed tomography imaging agents for the liver. J Med Chem. 1995;38(4):636–46.
Henning T, Weber AW, Bauer JS, Meier R, Carlsen JM, Sutton EJ, et al. Imaging characteristics of DHOG, a hepatobiliary contrast agent for preclinical microCT in mice. Acad Radiol. 2008;15(3):342–9.
Weber SM, Peterson KA, Durkee B, Qi C, Longino M, Warner T, et al. Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy is dependent on adequate contrast enhancement. J Surg Res. 2004;119(1):41–5.
Willekens I, Lahoutte T, Buls N, Vanhove C, Deklerck R, Bossuyt A, et al. Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC. Mol Imaging Biol. 2009;11(2):128–35.
Attia MF, Anton N, Chiper M, Akasov R, Anton H, Messaddeq N, et al. Biodistribution of X-ray iodinated contrast agent in nano-emulsions is controlled by the chemical nature of the oily core. ACS Nano. 2014;8(10):10537–50.
Badea CT, Fubara B, Hedlund LW, Johnson GA. 4-d micro-CT of the mouse heart. Mol Imaging. 2005;4(2):110–6.
Detombe SA, Ford NL, Xiang F, Lu X, Feng Q, Drangova M. Longitudinal follow-up of cardiac structure and functional changes in an infarct mouse model using retrospectively gated micro-computed tomography. Invest Radiol. 2008;43(7):520–9.
de Vries A, Custers E, Lub J, van den Bosch S, Nicolay K, Grull H. Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents. Biomaterials. 2010;31(25):6537–44.
Hallouard F, Briancon S, Anton N, Li X, Vandamme T, Fessi H. Iodinated nano-emulsions as contrast agents for preclinical X-ray imaging: impact of the free surfactants on the pharmacokinetics. Eur J Pharm Biopharm. 2013;83(1):54–62.
Li X, Anton N, Zuber G, Zhao M, Messaddeq N, Hallouard F, et al. Iodinated alpha-tocopherol nano-emulsions as non-toxic contrast agents for preclinical X-ray imaging. Biomaterials. 2013;34(2):481–91.
Trubetskoy VS. Polymeric micelles as carriers of diagnostic agents. Adv Drug Deliv Rev. 1999;37(1-3):81–8.
Trubetskoy VS, Gazelle GS, Wolf GL, Torchilin VP. Block-copolymer of polyethylene glycol and polylysine as a carrier of organic iodine: design of long-circulating particulate contrast medium for X-ray computed tomography. J Drug Target. 1997;4(6):381–8.
Torchilin VP, Frank-Kamenetsky MD, Wolf GL. Ct visualization of blood pool in rats by using long-circulating, iodine-containing micelles. Acad Radiol. 1999;6(1):61–5.
Ryan PJ, Davis MA, DeGaeta LR, Woda B, Melchior DL. Liposomes loaded with contrast material for image enhancement in computed tomography. Work in progress. Radiology. 1984;152(3):759–62.
Havron A, Seltzer SE, Davis MA, Shulkin P. Radiopaque liposomes: a promising new contrast material for computed tomography of the spleen. Radiology. 1981;140(2):507–11.
Seltzer SE, Davis MA, Adams DF, Shulkin PM, Landis WJ, Havron A. Liposomes carrying diatrizoate. Characterization of biophysical properties and imaging applications. Invest Radiol. 1984;19(2):142–51.
Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235–7.
Kao CY, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol. 2003;10(5):475–83.
Pannu HK, Thompson RE, Phelps J, Magee CA, Fishman EK. Optimal contrast agents for vascular imaging on computed tomography: iodixanol versus iohexol. Acad Radiol. 2005;12(5):576–84.
Mukundan Jr S, Ghaghada KB, Badea CT, Kao CY, Hedlund LW, Provenzale JM, et al. A liposomal nanoscale contrast agent for preclinical CT in mice. Am J Roentgenol. 2006;186(2):300–7.
Carruthers A, Melchior DL. Studies of the relationship between bilayer water permeability and bilayer physical state. Biochemistry. 1983;22(25):5797–807.
Seltzer SE, Blau M, Herman LW, Hooshmand RL, Herman LA, Adams DF, et al. Contrast material-carrying liposomes: biodistribution, clearance, and imaging characteristics. Radiology. 1995;194(3):775–81.
Elrod DB, Partha R, Danila D, Casscells SW, Conyers JL. An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid. Nanomedicine. 2009;5(1):42–5.
Kweon S, Lee HJ, Hyung WJ, Suh J, Lim JS, Lim SJ. Liposomes coloaded with iopamidol/lipiodol as a res-targeted contrast agent for computed tomography imaging. Pharm Res. 2010;27(7):1408–15.
Simon GH, Fu Y, Berejnoi K, Fournier LS, Lucidi V, Yeh B, et al. Initial computed tomography imaging experience using a new macromolecular iodinated contrast medium in experimental breast cancer. Invest Radiol. 2005;40(9):614–20.
Yordanov AT, Lodder AL, Woller EK, Cloninger MJ, Patronas N, Milenic D, et al. Novel iodinated dendritic nanoparticles for computed tomography (ct) imaging. Nano Lett. 2002;2(6):595–9.
Fu Y, Nitecki DE, Maltby D, Simon GH, Berejnoi K, Raatschen HJ, et al. Dendritic iodinated contrast agents with peg-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem. 2006;17(4):1043–56.
Pan D, Williams TA, Senpan A, Allen JS, Scott MJ, Gaffney PJ, et al. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J Am Chem Soc. 2009;131(42):15522–7.
Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166–72.
Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13(5):636–41.
Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med. 2009;50(6):959–65.
Van Herck JL, De Meyer GR, Martinet W, Salgado RA, Shivalkar B, De Mondt R, et al. Multi-slice computed tomography with n1177 identifies ruptured atherosclerotic plaques in rabbits. Basic Res Cardiol. 2010;105(1):51–9.
Ding J, Wang Y, Ma M, Zhang Y, Lu S, Jiang Y, et al. Ct/fluorescence dual-modal nanoemulsion platform for investigating atherosclerotic plaques. Biomaterials. 2013;34(1):209–16.
Glickson JD, Lund-Katz S, Zhou R, Choi H, Chen IW, Li H, et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol Imaging. 2008;7(2):101–10.
Song L, Li H, Sunar U, Chen J, Corbin I, Yodh AG, et al. Naphthalocyanine-reconstituted ldl nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine. 2007;2(4):767–74.
Allijn IE, Leong W, Tang J, Gianella A, Mieszawska AJ, Fay F, et al. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano. 2013;7(11):9761–70.
Hill ML, Corbin IR, Levitin RB, Cao W, Mainprize JG, Yaffe MJ, et al. In vitro assessment of poly-iodinated triglyceride reconstituted low-density lipoprotein: initial steps toward CT molecular imaging. Acad Radiol. 2010;17(11):1359–65.
Caride VJ, Sostman HD, Twickler J, Zacharis H, Orphanoudakis SC, Jaffe CC. Brominated radiopaque liposomes: contrast agent for computed tomography of liver and spleen: a preliminary report. Invest Radiol. 1982;17(4):381–5.
Mattrey RF, Long DM, Peck WW, Slutsky RA, Higgins CB. Perfluoroctylbromide as a blood pool contrast agent for liver, spleen, and vascular imaging in computed tomography. J Comput Assist Tomogr. 1984;8(4):739–44.
Bruneton JN, Falewee MN, Francois E, Cambon P, Philip C, Riess JG, et al. Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. Radiology. 1989;170(1 Pt 1):179–83.
Behan M, O'Connell D, Mattrey RF, Carney DN. Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results. Am J Roentgenol. 1993;160(2):399–405.
Mattrey RF. Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. Am J Roentgenol. 1989;152(2):247–52.
Li A, Zheng Y, Yu J, Wang Z, Yang Y, Wu W, et al. Superparamagnetic perfluorooctylbromide nanoparticles as a multimodal contrast agent for us, MR, and CT imaging. Acta Radiol. 2013;54(3):278–83.
Brown AL, Naha PC, Benavides-Montes V, Litt HI, Goforth AM, Cormode DP. Synthesis, X-ray opacity, and biological compatibility of ultra-high payload elemental bismuth nanoparticle X-ray contrast agents. Chem Mater. 2014;26(7):2266–74.
Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm. 2013;10(3):831–47.
Thakor AS, Jokerst J, Zavaleta C, Massoud TF, Gambhir SS. Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett. 2011;11(10):4029–36.
Wang B, Yantsen E, Larson T, Karpiouk AB, Sethuraman S, Su JL, et al. Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. Nano Lett. 2009;9(6):2212–7.
von Maltzahn G, Park JH, Agrawal A, Bandaru NK, Das SK, Sailor MJ, et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 2009;69(9):3892–900.
Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced raman nanoparticle tags. Nat Biotechnol. 2008;26(1):83–90.
Lee SE, Sasaki DY, Park Y, Xu R, Brennan JS, Bissell MJ, et al. Photonic gene circuits by optically addressable sirna-au nanoantennas. ACS Nano. 2012;6(9):7770–80.
Naha PC, Chhour P, Cormode DP. Systematic in vitro toxicological screening of gold nanoparticles designed for nanomedicine applications. Toxicol In Vitro. 2015;29(7):1445–53.
Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79(939):248–53.
Cai QY, Kim SH, Choi KS, Kim SY, Byun SJ, Kim KW, et al. Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray computed tomography in mice. Invest Radiol. 2007;42(12):797–806.
Kim D, Park S, Lee JH, Jeong YY, Jon S. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc. 2007;129(24):7661–5.
Jana NR, Gearheart L, Murphy CJ. Evidence for seed-mediated nucleation in the chemical reduction of gold salts to gold nanoparticles. Chem Mater. 2001;13(7):2313–22.
Turkevich J, Stevenson P, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc. 1951;11:55–75.
Huang P, Bao L, Zhang C, Lin J, Luo T, Yang D, et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011;32(36):9796–809.
Kattumuri V, Katti K, Bhaskaran S, Boote EJ, Casteel SW, Fent GM, et al. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and X-ray-contrast-imaging studies. Small. 2007;3(2):333–41.
Chanda N, Upendran A, Boote EJ, Zambre A, Axiak S, Selting K, et al. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nano-platform for computer tomography theranostics. J Biomed Nanotechnol. 2014;10(3):383–92.
Peng C, Li K, Cao X, Xiao T, Hou W, Zheng L, et al. Facile formation of dendrimer-stabilized gold nanoparticles modified with diatrizoic acid for enhanced computed tomography imaging applications. Nanoscale. 2012;4(21):6768–78.
Guo R, Wang H, Peng C, Shen MW, Pan MJ, Cao XY, et al. X-ray attenuation property of dendrimer-entrapped gold nanoparticles. J Phys Chem C. 2010;114(1):50–6.
Liu H, Xu Y, Wen S, Chen Q, Zheng L, Shen M, et al. Targeted tumor computed tomography imaging using low-generation dendrimer-stabilized gold nanoparticles. Chemistry (Easton). 2013;19(20):6409–16.
Ye K, Qin J, Peng Z, Yang X, Huang L, Yuan F, et al. Polyethylene glycol-modified dendrimer-entrapped gold nanoparticles enhance CT imaging of blood pool in atherosclerotic mice. Nanoscale Res Lett. 2014;9(1):529.
Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5(2):118–22.
Naha PC, Zaki AA, Hecht E, Chorny M, Chhour P, Blankemeyer E, et al. Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. J Mater Chem B Mater Biol Med. 2014;2(46):8239–48.
Bonitatibus Jr PJ, Torres AS, Goddard GD, FitzGerald PF, Kulkarni AM. Synthesis, characterization, and computed tomography imaging of a tantalum oxide nanoparticle imaging agent. Chem Commun (Camb). 2010;46(47):8956–8.
Bonitatibus Jr PJ, Torres AS, Kandapallil B, Lee BD, Goddard GD, Colborn RE, et al. Preclinical assessment of a Zwitterionic tantalum oxide nanoparticle X-ray contrast agent. ACS Nano. 2012;6(8):6650–8.
Oh MH, Lee N, Kim H, Park SP, Piao Y, Lee J, et al. Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping. J Am Chem Soc. 2011;133(14):5508–15.
Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(1):1–18.
Mohs AM, Lu ZR. Gadolinium(iii)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv. 2007;4(2):149–64.
Karagiannis P, Niumsawatt V, Rozen WM. An alternative contrast medium for computed tomographic angiography: gadolinium. Plast Reconstr Surg. 2014;133(6):900e–1e.
Gierada DS, Bae KT. Gadolinium as a CT contrast agent: assessment in a porcine model. Radiology. 1999;210(3):829–34.
Zeng C, Shi X, Wu B, Zhang D, Zhang W. Colloids containing gadolinium-capped gold nanoparticles as high relaxivity dual-modality contrast agents for CT and MRI. Colloids Surf B. 2014;123:130–5.
Alric C, Taleb J, Le Duc G, Mandon C, Billotey C, Le Meur-Herland A, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc. 2008;130(18):5908–15.
Huo D, He J, Li H, Yu H, Shi T, Feng Y, et al. Fabrication of au@ag core-shell NPs as enhanced CT contrast agents with broad antibacterial properties. Colloids Surf B. 2014;117:29–35.
Huo D, Ding J, Cui YX, Xia LY, Li H, He J, et al. X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia. Biomaterials. 2014;35(25):7032–41.
Chou SW, Shau YH, Wu PC, Yang YS, Shieh DB, Chen CC. In vitro and in vivo studies of fept nanoparticles for dual modal CT/MRI molecular imaging. J Am Chem Soc. 2010;132(38):13270–8.
Zhou Z, Kong B, Yu C, Shi X, Wang M, Liu W, et al. Tungsten oxide nanorods: an efficient nanoplatform for tumor CT imaging and photothermal therapy. Sci Rep. 2014;4:3653.
Jakhmola A, Anton N, Anton H, Messaddeq N, Hallouard F, Klymchenko A, et al. Poly-epsilon-caprolactone tungsten oxide nanoparticles as a contrast agent for X-ray computed tomography. Biomaterials. 2014;35(9):2981–6.
Mongan J, Rathnayake S, Fu Y, Wang R, Jones EF, Gao DW, et al. In vivo differentiation of complementary contrast media at dual-energy CT. Radiology. 2012;265(1):267–72.
Xing H, Bu W, Ren Q, Zheng X, Li M, Zhang S, et al. A NaYbF4: Tm3+ nanoprobe for CT and NIR-to-NIR fluorescent bimodal imaging. Biomaterials. 2012;33(21):5384–93.
Liu Y, Liu J, Ai K, Yuan Q, Lu L. Recent advances in ytterbium-based contrast agents for in vivo X-ray computed tomography imaging: promises and prospects. Contrast Media Mol Imaging. 2014;9(1):26–36.
Liu Y, Ai K, Liu J, Yuan Q, He Y, Lu L. A high-performance ytterbium-based nanoparticulate contrast agent for in vivo X-ray computed tomography imaging. Angew Chem Int Ed Engl. 2012;51(6):1437–42.
Xing H, Bu W, Zhang S, Zheng X, Li M, Chen F, et al. Multifunctional nanoprobes for upconversion fluorescence, MR and CT trimodal imaging. Biomaterials. 2012;33(4):1079–89.
Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, Upendran A, et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A. 2010;107(19):8760–5.
Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials. 2013;34(2):470–80.
Eck W, Nicholson AI, Zentgraf H, Semmler W, Bartling S. Anti-cd4-targeted gold nanoparticles induce specific contrast enhancement of peripheral lymph nodes in X-ray computed tomography of live mice. Nano Lett. 2010;10(7):2318–22.
Hainfeld JF, O'Connor MJ, Dilmanian FA, Slatkin DN, Adams DJ, Smilowitz HM. Micro-CT enables microlocalisation and quantification of her2-targeted gold nanoparticles within tumour regions. Br J Radiol. 2011;84(1002):526–33.
Chhour P, Naha PC, O'Neill SM, Litt HI, Reilly MP, Ferrari VA, et al. Labeling monocytes with gold nanoparticles to track their recruitment in atherosclerosis with computed tomography. Biomaterials. 2016;87:93–103.
Danad I, Fayad ZA, Willemink MJ, Min JK. New applications of cardiac computed tomography: dual-energy, spectral, and molecular CT imaging. JACC Cardiovasc Imaging. 2015;8(6):710–23.
Pan D, Schirra CO, Senpan A, Schmieder AH, Stacy AJ, Roessl E, et al. An early investigation of ytterbium nanocolloids for selective and quantitative “multicolor” spectral CT imaging. ACS Nano. 2012;6(4):3364–70.
Feuerlein S, Roessl E, Proksa R, Martens G, Klass O, Jeltsch M, et al. Multienergy photon-counting k-edge imaging: potential for improved luminal depiction in vascular imaging. Radiology. 2008;249(3):1010–6.
Cormode DP, Roessl E, Thran A, Skajaa T, Gordon RE, Schlomka JP, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology. 2010;256(3):774–82.
Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008;8(11):3715–23.
Pan D, Roessl E, Schlomka JP, Caruthers SD, Senpan A, Scott MJ, et al. Computed tomography in color: Nanok-enhanced spectral CT molecular imaging. Angew Chem Int Ed Engl. 2010;49(50):9635–9.
Acknowledgments
This work was supported by R01 HL131557 (D.P.C.), R00 EB012165 (D.P.C.), W. W. Smith Charitable Trust (D.P.C.), and the T32 HL007954 (P.C.). We also thank the University of Pennsylvania for startup funding.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chhour, P., Cheheltani, R., Naha, P.C., Litt, H.I., Ferrari, V.A., Cormode, D.P. (2017). Nanoparticles for Cardiovascular Imaging with CT. In: Bulte, J., Modo, M. (eds) Design and Applications of Nanoparticles in Biomedical Imaging. Springer, Cham. https://doi.org/10.1007/978-3-319-42169-8_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-42169-8_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42167-4
Online ISBN: 978-3-319-42169-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)